International Conference on NEFECON Real World Evidence 2025: Seven Research Studies on IgA Nephropathy at the Symposium
NEFECON®, a budesonide enteric-coated capsule, has been making waves in the medical community, particularly in the field of IgA nephropathy. Seven new abstracts presenting real-world evidence of NEFECON®'s efficacy and safety in treating IgA nephropathy will be showcased at the upcoming 18th International IgA Nephropathy Symposium (IIgANN 2025) in Prague, Czech Republic, from September 17 to 20, 2025.
The abstracts, authored by clinicians from several leading hospitals in China, have been approved for presentation at the symposium. These studies provide compelling evidence supporting the value of NEFECON® in reducing proteinuria and protecting renal function in IgA nephropathy patients.
One of the key studies, Abstract P-62, conducted by Xiaoyan Xiao from Qilu Hospital of Shandong University, Department of Nephrology, Jinan, Shandong, China, investigates early intervention with NEFECON® in IgA nephropathy. The study concludes that the treatment significantly reduces proteinuria and stabilizes renal function, and is well tolerated.
Another significant study, Abstract P-48, led by Ming Fang from the Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Renal Translational Medicine Center of Liaoning Province, Dalian, China, focuses on six-month NEFECON® therapy in patients with IgA nephropathy and renal insufficiency. The study finds that the treatment may stabilize kidney function and reduce proteinuria, with favorable tolerability in high-risk IgA nephropathy populations.
Moreover, Abstract P-64, authored by Junjun Zhang from The Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, presents a real-world observational study of NEFECON®'s clinical outcomes and safety in Chinese IgA nephropathy patients. The study demonstrates sustained renoprotective effects, particularly in those with preserved renal function, and a favorable safety profile.
The clinical value of NEFECON® has been highlighted across three key dimensions: etiological treatment, early intervention, and long-term treatment. This value is further underscored by the fact that NEFECON® has been included in China's National Reimbursement Drug List (NRDL) since November 2024, making it more accessible to patients in need.
NEFECON®'s journey to becoming the world's first IgAN treatment to receive full approval from multiple regulatory bodies is noteworthy. It has received approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, as well as in other Asian territories where Everest Medicines holds the rights.
In August 2025, the supplemental application for the production expansion of NEFECON® was officially approved by the NMPA, further facilitating its widespread use.
However, it's important to note that while the studies present promising results, potential concerns about NEFECON®'s impact on the hypothalamic-pituitary-adrenal axis, particularly in pediatric patients, have been raised, as highlighted in Abstract P-63, authored by Yu Zhang from the Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
As the 18th IIgANN approaches, the medical community eagerly awaits the presentation of these new abstracts, which could pave the way for improved treatment options for IgA nephropathy patients worldwide.
